A Phase 2a Study to Evaluate the Safety and Tolerability of OCR-002 (ornithine phenylacetate) in the Treatment of Patients with Acute Liver Failure/Severe Acute Liver Injury (STOP-ALF) -- A Multi-Center Group to Study Acute Liver Failure

Project: Research project

Project Details

Description

Evaluating the Safety and Tolerability of OCR-002 (ornithine phenylacetate) in the Treatment of Patients with Acute Liver Failure/Severe Acute Liver Injury (STOP-ALF) We expect to enroll 6 patients in this part of the project.
StatusFinished
Effective start/end date9/18/158/31/19

Funding

  • University of Texas Southwestern Medical School (GMO-170910 // 5U01DK058369-19)
  • National Institute of Diabetes and Digestive and Kidney Diseases (GMO-170910 // 5U01DK058369-19)

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.